Hemant Surgical Industries: Two Government Orders Behind a 117% Revenue Jump

Large government orders more than doubled this small Mumbai medical-device maker's revenue in a single year — funded in part by a share count that grew nearly 40% over the same stretch.

Hemant Surgical Industries Ltd - Share price: ~₹614 (as of Sept 24, 2026 close — check the live price before acting) - Market cap: ~₹892 crore - P/E: ~52.9x (vs. Poly Medicure ~54.6x — a much larger listed company that HSIL itself compared with in its IPO prospectus)

What the company actually makes

Hemant Surgical Industries (HSIL) makes and imports medical disposables and surgical equipment in Mumbai. Its products include dialysis machines, oxygen concentrators, nebulisers under its own AERO brand, ultrasound machines, and refurbished dialysis equipment. It's also the exclusive Indian importer for Japan's JMS Co. Ltd.

Founded in 1985 and incorporated as Hemant Surgical Industries Limited in 1989, it's been in this business for close to four decades — this isn't a new startup dependent on a single product.

It's also important to know where the shares trade: HSIL is listed on the BSE SME platform, not the mainboard. It listed on June 5, 2023, raising ₹25 crore at an IPO price of ₹90 per share, with a market lot of 1,600 shares. SME stocks generally trade in larger lots and with much thinner daily volumes than mainboard stocks — so even an ordinary buy or sell order can move the price more, and getting in or out in size can take longer. At ~₹614, the stock is up roughly 6.8x from its IPO price in a little over three years.

After the FY26 close, HSIL also moved into a new area: on June 1, 2026, it acquired a 66.66% stake in Lifesenz Cancer Research Labs Private Limited by subscribing to its equity shares, making it a subsidiary. This is disclosed in HSIL's own FY26 Annual Report, but the report gives no financial detail on Lifesenz itself (no revenue, profit, or purchase price) — worth watching for what this actually contributes once more is disclosed, rather than assuming it's material yet.

The orders that rewrote the growth story

For most of its listed life, HSIL was a small business growing slowly: revenue was ₹106 crore in FY2023-24 and barely moved to ₹107 crore in FY2024-25. Then FY2025-26 was very different — consolidated revenue jumped roughly 117% to ₹232 crore, while profit after tax jumped 126% to ₹18.19 crore.

Government orders explain a large part of that change, and they're not from just one buyer. The biggest by far is the Central Medical Service Society (CMSS), under the Ministry of Health and Family Welfare: a ₹82.89 crore order in September 2025 for handheld portable X-ray machines (completed by December 31, 2025), followed by a further ₹264.33 crore of CMSS purchase orders disclosed in February 2026 (dated December 2025) for portable X-ray equipment — flat panel detectors, X-ray generators, and related hardware — with delivery in stages through September 30, 2026. HSIL's own FY26 Annual Report also describes a separate rate contract with the Government of Bihar, under its Zoncare brand, for 43 ultrasound machines, 700 multi-para patient monitors, 112 ECG machines, and a batch of veterinary portable Doppler units — no rupee value was disclosed for this one, but it shows the government-contract pattern isn't limited to the federal CMSS orders alone.

Mostly one big customer, but not only one. The CMSS orders are large enough on their own to have significantly changed HSIL's growth profile — a strong boost while they're being executed, but also a sign that a large part of the company's recent growth rides on a few buyers' procurement cycles rather than broad-based growth across its whole business. The Bihar contract shows the company can win government business beyond CMSS, which is a mildly reassuring diversification signal, even though its size isn't disclosed.

A real-world example: how much the share count has grown

In September 2025, HSIL raised money on a preferential basis — issuing new shares and convertible warrants directly to a named set of investors rather than the public. On September 18, 2025, it allotted 25,98,400 new equity shares at ₹197 each (~₹51.2 crore raised) to a broad group including the Singularity funds, Wealthwave Capital Fund, and several individual investors. Alongside this, on September 16, 2025, it allotted 20,99,200 convertible warrants, also at ₹197 (25% paid upfront) — most to the same institutional investors, but 6,00,000 of them to the company's own promoter-directors (Hanskumar Shamji Shah, Hemant Praful Shah, and Kaushik Hanskumar Shah — 2,00,000 warrants each).

In May 2026, holders of 14,99,200 of those warrants (the non-promoter institutional portion, including the Singularity funds) paid the remaining 75% (₹147.75 per warrant) and converted them into equity shares. The promoters' 6,00,000 warrants haven't converted yet, as of the last disclosure — a further dilution overhang if and when they do.

Here's what that did to the share count and to promoter ownership, straight from HSIL's own audited financial statements:

Date Event Shares outstanding Increase ------------ March 31, 2025 — (starting point) 1,04,40,000 — Sept 18, 2025 Preferential equity allotment 1,30,38,400 +24.9% May 15, 2026 Warrant conversion (institutional) 1,45,37,600 +11.5%

Combined, these two rounds added 40,97,600 new shares — a 39.3% increase over the pre-September-2025 base, in about eight months. Promoter holding fell from 70.53% (March 2025) to 56.48% (March 2026) to 52.83% (May 2026) — a roughly 17.7-percentage-point drop, considerably more than a single quarter's dilution.

At ~₹614, the converted shares are worth roughly 3.1x the full ₹197 the institutional investors committed to pay. That's a genuine vote of confidence — and worth noting, the promoters bought into the same round on the same terms, so this wasn't purely outside money diluting insiders. But the timing also matters: everyone committed to this fundraise in September 2025, before either CMSS order was placed (December 2025) or publicly disclosed (February 2026) — a bet made ahead of the government-order news, not fresh buying at today's much higher price.

Fast growth, thin history, slower collections

Year Revenue (₹ Cr) Net profit (₹ Cr) --------- FY2023-24 106 10 FY2024-25 107 8 FY2025-26 232 18.19

A few things stand out in the numbers, beyond the headline growth:

- 5-year sales CAGR of 31% — strong, but the recent FY26 jump has a big influence on it, so it shouldn't be read as a smooth, steady 31%-a-year story. - ROE of 16.9% and ROCE of 18.9% — respectable for a company this size, and comfortably above its cost of borrowing. - Debt-to-equity of about 0.29 (₹50 crore borrowings against roughly ₹137 crore of equity and reserves) — not a particularly high debt load. - Debtor days have risen from 70 to 106 — customers are taking noticeably longer to pay, plausibly linked to serving a large government buyer, which typically pays on its own slower administrative timeline. - Operating cash flow was negative — roughly ₹32 crore — in FY2025-26, despite ₹18.19 crore of reported profit. This is the single most important number here: the company reported a profit, but its operations actually consumed cash during the year. Combined with the rising debtor days, it means the new revenue hasn't yet turned into cash in the bank. Profit and cash are not the same thing. - No dividend has been paid despite consistent profitability — not unusual for a smaller company reinvesting in growth, but worth noting for anyone expecting income alongside capital appreciation. - Promoter holding is down to 52.83% — see the fuller dilution picture above; this reflects the preferential share issues, not promoters selling out. DIIs now hold 19.94% and FIIs a negligible 0.14%, with the public holding the remaining 27.10%.

How it stacks up against Poly Medicure

Poly Medicure (NSE: POLYMED) is far larger and has a more diversified, export-driven business — and it's the listed company HSIL itself compared against in its IPO prospectus, making it a useful benchmark for the sector.

Metric Hemant Surgical Industries Poly Medicure --------- Market cap ~₹892 crore ₹17,479 crore P/E ~52.9x ~54.6x FY2025-26 revenue ₹232 crore ₹1,875 crore FY2025-26 net profit ₹18.19 crore ~₹321 crore

HSIL has almost the same P/E as a company nearly 20 times its size, with a far longer track record of diversified, recurring export-driven revenue. A similar P/E isn't automatically a warning sign — a much smaller company with a genuine growth catalyst can command a high valuation — but it does mean the current share price already assumes the government-order-driven growth continues, or that the company finds something comparable once these orders are done. HSIL doesn't look cheap simply because it's growing fast right now.

Management's own outlook, and one open legal dispute

HSIL's FY26 Annual Report includes a short "Prospect & Outlook" statement from management: "The management is of the view that the future prospects of your Company are bright and the performance in the current year is expected to be very well. The committed customers of the Company are expected to place more orders, which ultimately affect the top line of the Company, positively." That's the whole of it — no specific revenue or profit target, no named number, just a general expectation that existing customers (almost certainly including CMSS) place repeat orders. Treat it as management's own hope for the year ahead, not a forecast or a promise — the report itself carries a standard cautionary statement that these forward-looking remarks may not materialise as described.

The same report cites broader industry research (via IBEF and its own estimates) projecting India's medical devices market growing from roughly $15-16 billion (2025) to nearly $50 billion by 2030 — a 20-27% industry-wide CAGR. That's a genuine tailwind for the sector HSIL operates in, though a rising industry doesn't guarantee any one company captures its share of that growth.

One more thing the audit report surfaces that the article hasn't covered yet: HSIL has an active dispute with customs authorities, worth ₹3.56 crore, over the tax classification of surgical tapes — the company paid the disputed amount under protest and has an appeal pending before the Supreme Court. There are also smaller disputed dues (₹18.01 lakh income tax/TDS, ₹70.61 lakh GST) not yet deposited due to ongoing disputes. None of this is disclosed as likely to affect the company's ability to continue operating, but it's a real, open legal risk a reader should know about.

Should you chase it?

HSIL's story is built on real, disclosed government orders that have genuinely transformed its revenue and profit in one year, backed by nearly four decades of operating history and a credible institutional investor base. That's meaningfully more substance than many SME small-caps can claim.

But the risks are just as real: a large part of this year's growth comes from orders concentrated with one dominant government buyer (CMSS), not broad growth across the whole business; the share count grew nearly 40% in eight months through preferential placements, meaningfully diluting existing shareholders; operating cash flow turned negative even as reported profit rose sharply, while debtor days increased — together, a sign the reported profit hasn't yet turned into cash; there's no dividend cushion; a ₹3.56 crore customs dispute sits unresolved at the Supreme Court; and as a thinly-traded BSE SME stock, an ordinary buy or sell can move the price more than it would on the mainboard. Management's own outlook is generically positive with no hard numbers attached. The valuation, at a P/E close to a much larger, more diversified sector leader, already reflects a fair amount of optimism about what comes after the larger CMSS order finishes executing through September 2026 — and about that revenue eventually turning into cash.

Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.

Sources

- Hemant Surgical Industries Ltd — Screener.in - Hemant Surgical Industries Ltd (consolidated) — Screener.in - Poly Medicure Ltd — Screener.in - Hemant Surgical Industries IPO details — Chittorgarh - Hemant Surgical Industries Secures ₹264.33 Crore Order from Central Medical Service Society — ScanX - Microcap stock hits upper circuit after receiving ₹83 Cr order from CMSS — Trade Brains - HSIL FY25-26 Integrated Annual Report and Notice of 37th AGM (filed Sept 4, 2026) — BSE corporate filing - HSIL corporate announcements — BSE